Single nucleotide polymorphism in prohibitin 3' untranslated region and breast-cancer susceptibility.

The RNA encoded by the 3' untranslated region of the prohibitin gene arrests cell proliferation by blocking the transition between the G1 and S phases of the cell cycle. The product of a variant allele (T allele) is inactive. We did a case-control study of prohibitin genotype in 205 women with breast cancer and 1046 healthy controls. The results showed an association between the T allele and breast cancer in women who reported a first-degree relative with the disease (odds ratio 2.5, p=0.005). An even stronger association was found in a subset of women diagnosed at or before age 50 years (4.8, p=0.003). These data suggest that prohibitin genotyping has value in assessing risk of breast cancer in women aged 50 years or younger with at least one first-degree relative with the disease.

Case report of a newborn with a posterior thoracic midline congenital hemangiopericytoma of the back.

The posterior thoracic midline location is an unusual site for a congenital hemangiopericytoma. The authors report such a case that caused near fatal exsanguination of a newborn after vaginal delivery. Magnetic resonance imaging (MRI) studies of the mass were completed after hemostasis. These studies showed a well-defined border between the tumor and underlying trapezius muscle. The mass was removed successfully surgically and presumed initially to be a teratoma. Pathological diagnosis of the tumor was hemangiopericytoma with low malignant potential. After a 9-day hospital course, the patient was discharged with recovering hepatic and renal function.

New molecular targets for cholesterol-lowering therapy.

The use of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) in randomized clinical trials has established that cholesterol-lowering treatment reduces the risk of both cardiovascular and total mortality. This reduction in risk occurs in patients with or without existing cardiovascular disease and in patients with high or average plasma cholesterol concentrations. Aggressive treatment to lower plasma cholesterol has been shown to slow progression of atherosclerosis and in some instances may be as successful as angioplasty in reducing ischemic events. These studies suggest that reduction of plasma cholesterol to levels even below 100 mg/dl might be desirable. New targets for cholesterol-lowering therapy with mechanisms of action different from the statins have been identified. One of these targets is the Na(+)-dependent bile acid transporter that is expressed in the terminal ileum. This protein is responsible for recycling bile acids from the intestine to the liver. Several compounds that demonstrate the ability to decrease transporter activity and to lower plasma cholesterol have been investigated. Absorption of cholesterol from the small intestine is another potential target. Compounds that inhibit cholesterol absorption may act by interacting stoichiometrically with cholesterol within the intestinal lumen or substoichiometrically, presumably within the enterocyte. Finally, the transcriptional regulation of cholesterol 7alpha-hydroxylase by members of the nuclear receptor superfamily provides at least two other molecular targets for cholesterol-lowering drugs.

PET hydroxyephedrine imaging of neuroblastoma.

UNLABELLED: The goals of this investigation were to characterize the uptake of 11C-hydroxyephedrine (HED) in neuroblastoma and to determine the feasibility and potential advantages of utilizing this compound as a tumor imaging agent. METHODS: Seven patients with known or subsequently proven neuroblastoma were studied. Each patient underwent PET scanning with 11C-HED. Six of seven patients underwent scintigraphy with [123I]meta-iodobenzylguanidine (MIBG), and two patients were also studied with [18F]FDG PET. For six patients, CT or MR images were available for comparison. RESULTS: Neuroblastomas were located by PET scanning with 11C-HED in all seven patients. The uptake of HED into neuroblastomas was rapid; tumors were evident on images within 5 min postintravenous injection. Those lesions in the field of view of the PET camera were also identified on [123I]MIBG scintigraphic images. In two patients, tumor deposits in the abdomen were better visualized with MIBG scintigraphy due to relatively less hepatic accumulation of MIBG than HED. CONCLUSION: PET scanning with HED for neuroblastoma results in high quality functional images of the tumors that can be obtained within minutes following injection.

Transcriptional regulation of endothelial constitutive PGHS-1 expression by phorbol ester.

Human endothelial cells contain two isoforms of prostaglandin H synthase (PGHS). PGHS-1 is constitutively expressed, whereas PGHS-2 is inducible. To determine whether expression of PGHS-1 is regulated, we treated cultured human umbilical vein endothelial cells (HUVEC) with phorbol 12-myristate 13-acetate (PMA) or its inactive analogue and measured PGHS-1 mRNA levels by Northern analysis and competitive polymerase chain reaction. PMA increased PGHS-1 mRNA levels determined by both techniques in a time- and concentration-dependent manner. The mRNA level was increased about twofold over the basal level after 4-6 h of PMA (10-50 nM) treatment. The level of PGHS-1 protein was similarly increased by PMA. Stimulation of PGHS-1 mRNA levels was abrogated by cycloheximide, actinomycin D, staurosporine, or calphostin C. The 5'-promoter activity of human PGHS-1 gene was increased twofold over the basal level by PMA in NS-20 cells. These results indicate that the constitutive PGHS-1 in HUVEC is transcriptionally stimulated by PMA in a protein kinase C-dependent manner.

Development and use of a receptor antibody to characterize the interaction between somatostatin receptor subtype 1 and G proteins.

The signal transduction pathways regulated by somatostatin receptor subtype 1 (sst1) have been difficult to define because of the variability observed when this receptor is expressed in different cell types by transfection and because pharmacological approaches are inadequate to distinguish sst1 receptor subtypes. To study the sst1 receptor in its endogenous environment, we developed a polyclonal antibody to a 15-amino acid peptide corresponding to a unique sequence in the receptor carboxyl terminus. The peptide antibody routinely precipitated 70% of the soluble [125I-Tyr11]somatostatin/receptor complex prepared from Chinese hamster ovary-K1 cells expressing the sst1 receptor but precipitated < 1% of the complex from cells expressing other sst receptor subtypes. Photoaffinity-labeled sst1 receptor was also specially immunoprecipitated and migrated as a broad 60-kDa band on sodium dodecyl sulfate polyacrylamide gels. The observation that sst receptors from GH4C1 pituitary cells were immunoprecipitated by the antibody and that receptors from AR4-2J pancreatic acinar cells were not indicated that only the former expressed sst1 receptor protein. Because reverse transcription-polymerase chain reaction showed that GH4C1 cells contained both sst1 and sst2 receptor mRNA, immunoprecipitation permitted the sst1 receptor to be separated from the other receptors present. Two observations showed that G proteins were coprecipitated with sst1 receptors from GH4C1 cells. First, pertussis toxin pretreatment markedly decreased hormone binding in the immunoprecipitate. Second, the addition of 20 microM guanosine-5'-(gamma-thio)triphosphate to the immunoprecipitated [125I-Tyr11]somatostatin/receptor complex stimulated the rate of dissociation of bound ligand by 10-fold. Interestingly, however, the dissociation rate of approximately 30% of the ligand/receptor complex was unaffected by guanosine-5'-(gamma-thio)triphosphate. In summary, we have developed an sst1 receptor-specific antibody and used it to show that sst1 receptors endogenously expressed in GH4C1 pituitary cells couple primarily to pertussis toxin-sensitive G proteins. Furthermore, these receptors exist in two distinct high affinity states distinguished by their GTP sensitivity.

Toxicity of endogenous and environmental estrogens: what is the role of elemental interactions?

Many naturally occurring and man-made chemicals present in the environment possess estrogenic activity. Examples include plant and fungal products, pesticides, plasticizers, and other agricultural and industrial chemicals. These environmental estrogens as well as endogenous ovarian estrogens are thought to initiate their physiological actions in target tissues largely via interactions with a nuclear receptor system. The resultant estrogen-receptor complex in turn affects transcription via its interactions with nucleotide sequences known as estrogen response elements (EREs) present in the regulatory regions of hormone responsive genes. A "consensus" ERE sequence GGTCAnnnTGACC was originally identified in the vitellogenin genes of birds and amphibians, but it is now clear that most naturally occurring EREs differ from this sequence in one or more bases. We and others have obtained both in vivo and in vitro data suggesting a differential interaction of receptor complexes containing different ligands with the multiple EREs present in mammalian systems. This raises the possibility that the toxicity of environmental estrogens may arise in part from a differential pattern of ERE activation by environmental compounds relative to endogenous ovarian estrogens. The experimental basis for such a paradigm and its toxicological implications are discussed in this paper.

Topology of prostaglandin H synthase-1 in the endoplasmic reticulum membrane.

Prostaglandin H synthase-1 is an integral endoplasmic reticulum membrane protein which catalyzes a key control step in prostaglandin biosynthesis. The overall arrangement of the prostaglandin H synthase-1 polypeptide with respect to the endoplasmic reticulum membrane was examined in transiently transfected COS-1 cells, using immunofluorescence microscopy. A bacterial toxin, streptolysin-O, was used for selective plasma membrane permeabilization and a detergent, saponin, for general membrane permeabilization. Treated cells were probed with six antibodies specific for particular prostaglandin H synthase-1 peptide segments and one antibody specific for an inserted viral reporter epitope. Control experiments established that actin, a cytoplasmic marker, was accessible to fluorescein-labeled phalloidin after streptolysin-O treatment, whereas antibodies against protein disulfide isomerase, an endoplasmic reticulum lumenal marker, bound only after saponin treatment, Using this approach to investigate prostaglandin H synthase-1, it was found that streptolysin-O treatment was sufficient to obtain staining of intracellular membranes by antibodies specific for the endogenous C-terminal segment, for the viral reporter inserted at the C-terminus, and for the protease-sensitive region near arg277. In contrast, saponin treatment was necessary for staining by antibodies specific for peptides spanning residues 51-66, 156-170, and 377-390. Antibodies targeted against residues 483-496 did not stain transfected cells even after saponin permeabilization, although they did bind to detergent-solubilized prostaglandin H synthase-1. These results indicate that the C-terminus and arg277 regions of the synthase can be exposed on the cytoplasmic side of the endoplasmic reticulum membrane, whereas regions near N-glycosylation sites are confined to the endoplasmic reticulum lumen and residues 483-496 are inaccessible from either side of the endoplasmic reticulum membrane.

Neoplasms in a pediatric population: 2-[F-18]-fluoro-2-deoxy-D-glucose PET studies.

PURPOSE: To assess the uptake of 2-[fluorine-18]-fluoro-2-deoxy-D-glucose (FDG) in common and uncommon tumors in children and to develop a method for performing positron emission tomography (PET) studies in children with malignant neoplasms. MATERIALS AND METHODS: Twenty-two pediatric patients with known or suspected malignancies (27 scans) underwent FDG PET. Tumor uptake of FDG was measured on PET scans. RESULTS: Tumor uptake of FDG was detected in 17 of 21 patients with malignant disease. Neuroblastomas and their metastases (including those that did not absorb metaiodobenzylguanidine) intensely accumulated FDG. In a patient with Ewing sarcoma, FDG PET showed two foci of metastatic disease not evident on bone scans. In two patients, PET showed that large areas of the tumor were necrotic. CONCLUSION: FDG PET is feasible, is useful in the study of tumors in children, and may provide unique, clinically important information.

Prostaglandin H synthase-1: evaluation of C-terminus function.

The first committed step in prostaglandin biosynthesis is catalyzed by prostaglandin H synthase, an enzyme localized to the endoplasmic reticulum (ER) membrane in a variety of cells. Several types of C-terminal region peptide sequence motifs have been found to lead to ER retention of other proteins. We have tested the potential role for such signals in the ER localization and catalytic activity of human isoform-1 of the synthase (PGHS-1). PGHS-1 mutants with alterations in the C-terminus designed to disrupt potential retention signals were expressed in transfected COS-1 cells. The mutations included: substitution of valine for the ultimate leucine residue (position 600) to disrupt a KDEL-type signal, substitution of a neutral glutamine for arginine at position 595 to disrupt signals based on positive charge, and deletion of the last six residues, to remove all of the wild-type extreme C-terminus. The subcellular localization of each recombinant PGHS-1 was assessed by differential centrifugation and by immunofluorescence microscopy. None of the mutations led to a significant change in the distribution of PGHS-1 between microsomes and other cellular fractions. Immunostaining of wild-type PGHS-1 and all of the mutants colocalized with that of protein disulfide isomerase, an ER marker protein. However, mutation of the terminal leucine or deletion of the last six residues did lead to loss of cyclooxygenase activity. Mutation of the terminal leucine also altered the pattern of fragments produced by limited proteolysis, indicating that this mutation led to changes in the polypeptide folding which might account for the loss of activity. The results indicate that the extreme C-terminal region is important to the functional integrity of PGHS-1, but it is not an essential part of the intracellular targeting mechanism.

Both Sertoli and peritubular cells respond to androgens with increased expression of an androgen response element reporter.

To explore the ability of androgens to affect gene expression in Sertoli and peritubular cells in vitro, constitutively expressed pSV2-Luc and a regulated reporter containing an androgen response element (MMTV-Luc) were transiently transfected into these cells. Reporter expression was markedly affected by cell density and maturational age. Mibolerone-stimulated MMTV-Luc expression increased in Sertoli cells with animal age between 15 and 25 days, consistent with the developmental increase in androgen receptor concentration, but was not markedly age-dependent in peritubular cells. The antiandrogen hydroxyflutamide inhibited stimulation of MMTV-Luc expression by 1 and 10 nM testosterone in both Sertoli and peritubular cells, consistent with an androgen receptor-mediated event. In contrast, dexamethasone at 1 and 10 nM elicited no effect in Sertoli cells, but stimulated MMTV-Luc expression in peritubular cells. In this study, the androgen receptor/glucocorticoid receptor ratio was 2.4 and 0.06 in Sertoli and peritubular cells, respectively. Cotransfection of Sertoli and peritubular cells with a plasmid expressing the rat androgen receptor further increased the androgen-stimulated expression of MMTV-Luc. These data demonstrate the functionality of the androgen receptors in both Sertoli and peritubular cells in culture. Receptor expression appears to be a limiting factor in the response. The data are consistent with potential roles for both Sertoli and peritubular cells in androgen-mediated transcriptional events in the testis.

SAS, a gene amplified in human sarcomas, encodes a new member of the transmembrane 4 superfamily of proteins.

Amplification of 12q13-14 occurs in a subset of human sarcomas including malignant fibrous histiocytoma and liposarcoma. This chromosomal region has previously been found to include a number of growth-related genes including the GLI proto-oncogene and the p53-associated protein, MDM2. We now report the characterization of SAS (sarcoma amplified sequence), a novel transcript found in this region. Sequence analysis demonstrates that SAS is a novel member of a transmembrane protein family (transmembrane 4 superfamily or TM4SF) thought to be involved in growth-related cellular processes. This observation adds a TM4SF protein to the cluster of genes at 12q13-14 frequently amplified in human sarcomas.

Steroid hormone-induced expression of oncogene encoded nuclear proteins.

In this article we have attempted to review the literature on the regulation of nuclear protooncogene expression by steroid hormones and other small molecules that interact with receptors of the steroid/thyroid superfamily. Until about 5 years ago, there were relatively few reports of steroidal regulation of cellular oncogenes, but hundreds of papers on this topic have appeared since then. This demonstrates the intense interest in this area that has developed recently. It now been demonstrated that all the major classes of steroid hormones control expression of nuclear protooncogenes in one or more systems. Given the actions of these proteins as transcription factors and their central role in cellular communications systems, it seems likely that they play a key role in mediating the biological effects of steroids on processes such as proliferation and differentiation. To date, most of the work in this general area has focused primarily on the regulation of three genes: c-fos, c-jun, and c-myc. However, a quick glance at the table of nuclear protooncogenes in the introduction of this article indicates that over 40 nuclear protooncogenes are now recognized. For the large majority of these, regulatory effects of steroids and related molecules have not yet been reported. Hence, we predict that reports in this general area of research will continue to appear at a very rapid rate over the next few years. In addition, we have tried to provide enough background information for readers to get an overview of the regulation of nuclear protooncogene expression by nonsteroidal factors. We felt this information was important to emphasize that steroid hormones represent only one of the many classes of regulatory molecules that control expression of nuclear protooncogenes. Thus, an important area for future research will be to understand how these multiple regulatory systems interact to control expression of this important class of cellular oncogenes and the biological processes that they mediate.

Resistance to dietary-induced hypercholesterolemia exhibited by a unique strain of New Zealand white rabbits.

The search for a precise metabolic explanation for the capacity of some individuals to resist the development of dietary-induced hypercholesterolemia, thus avoiding attendant cardiovascular atherosclerotic complications, has long been the focus of our research. From 1 New Zealand white rabbit that failed to show any cholesterolemic response, we have, over the course of 10 years, established a partially inbred strain of strongly cholesterol-resistant rabbits. This achievement has resulted in the production of a large number of cholesterol-resistant animals for study; more importantly, it has shown that a strong genetic factor operates in dietary regulation of plasma cholesterol levels. We have focused our research on the different possibilities associated with this genetic predisposition. Since the cholesterol-resistant rabbits do not accumulate cholesterol or its esters in plasma or in any tissue compartments, we investigated several biochemical pathways involved in cholesterol metabolism. We have recently concentrated on the enzyme cholesterol 7 alpha-hydroxylase and liver bile acid metabolism. We have cloned the complete gene and partial cDNAs for cholesterol 7 alpha-hydroxylase from both normal and cholesterol-resistant rabbits. This has allowed the discovery of changes in the transcription of this gene in the cholesterol-resistant rabbits compared with normal littermates. These cholesterol-resistant rabbits have provided a model demonstrating that there are biological means to prevent large dietary loads of cholesterol from accumulating in plasma or tissues. Our hypothesis is that cholesterol-resistant animals increase cholesterol turnover by increasing bile acid excretion, thus providing a way to reduce plasma cholesterol of either dietary or endogenous origin. The methods and observations of our research are presented chronologically in this review.

Gene therapy for vascular diseases.

Gene transfer by virus- and liposome-mediated vectors has potential for treating genetic diseases, cancer, and cardiovascular diseases. In this article, we discuss the general principle and techniques for gene transfer and the specific issues facing therapy for vascular diseases. We also propose a strategy for using virus-mediated gene transfer to restore the vasoprotective function of the vascular wall, thereby preventing vascular thrombosis. Experimental data from ongoing work in our laboratories are presented to illustrate the importance of this approach in vascular gene transfer therapy.

Bile acid excretion and cholesterol 7 alpha-hydroxylase expression in hypercholesterolemia-resistant rabbits.

We have developed a partially inbred substrain of New Zealand white rabbits (CRT/mlo) that are resistant to the hypercholesterolemia that accompanies cholesterol feeding to normal rabbits. The plasma cholesterol concentration of normal rabbits increases dramatically from about 30 mg/dl to > 300 mg/dl after they are fed a 0.1% cholesterol-enriched diet for 3-4 months. Cholesterol-fed CRT/mlo animals, however, maintain a cholesterol level of about 30 mg/dl during the entire cholesterol feeding period. In addition to the low plasma cholesterol level, measurements of cellular cholesterol indicate that the hepatic cholesterol content of the cholesterol-fed resistant rabbit remains markedly lower than it does in normal animals fed the same diet. The only mechanism for removal of significant quantities of cholesterol carbon from the body is via the fecal excretion of cholesterol, neutral sterol metabolites, and bile acids. In comparison to the basal, low-cholesterol diet, we observed that cholesterol-fed resistant rabbits had increased excretion of lithocholic acid, while excretion of this bile acid by cholesterol-fed normal rabbit remained similar to basal diet levels. Deoxycholic acid excretion, the other main bile acid excreted in the feces of rabbits, was decreased in response to cholesterol challenge in animals with either resistant or normal phenotypes, but the decrease was significantly less in the resistant rabbits. Thus, the resistant rabbits excreted relatively more lithocholic and deoxycholic acid than did the cholesterol-fed normal rabbit. The difference in bile acid excretion was also manifest by a higher than normal level of cholesterol 7 alpha-hydroxylase activity and cholesterol 7 alpha-hydroxylase mRNA in the livers from resistant versus normal rabbits. As cholesterol 7 alpha-hydroxylase is the putative rate-limiting step of bile acid synthesis, we believe that the increased excretion of bile acids by resistant animals is due, at least in part, to increased levels of cholesterol 7 alpha-hydroxylase expression.